AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter

A manufacturing issue at a plant in Texas has resulted in a complete response letter from the FDA, dashing AstraZeneca's hopes that its potential best-in-class treatment for hyperkalemia, ZS-9, would be approved in this year's first half – but the good news is that no new clinical data is required on the drug.

Prescription

The regulatory timeline for AstraZeneca PLC's promising potassium-binding compound ZS-9 has been derailed for the time being by a complete response letter from the FDA due to manufacturing deficiencies found by investigators during a pre-approval inspection at a plant making the medicine in Coppell, Texas.

Still, the British drug maker – which acquired the asset when it bought US-based ZS Pharma Inc. last year...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip